LANTERN PHARMA INC. (LTRN)
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business